文献速递妇科

腹腔镜病灶评估在新诊断晚期卵巢癌中的成本效果

Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2021-01-31

本研究从医疗支付方角度进行成本效果分析,比较标准评估策略与腹腔镜策略在晚期卵巢癌患者中的差异。腹腔镜策略平均增加成本7034美元,但额外获得4.1个月质量调整无进展生存期,增量成本效果比为每增加一个质量调整无进展生存年20376美元。结论认为腹腔镜是改善初始治疗规划的成本有效方法。

要点

  • 腹腔镜策略平均增加成本7034美元,额外获得4.1个月质量调整无进展生存期。
  • 增量成本效果比为每增加一个质量调整无进展生存年20376美元,低于50000美元/年的支付意愿阈值。
  • 腹腔镜策略在支付意愿阈值范围内均具有成本效果。

核心结论

  • 腹腔镜是改善新诊断晚期卵巢癌患者初始治疗规划的成本有效方法。

研究设计与样本

  • 从医疗支付方角度进行的成本效果分析,比较标准评估策略与腹腔镜策略。
  • 采用微模拟模型,包括诊断检查、手术和辅助治疗、围手术期并发症及无进展生存期。
  • 模型参数来源于文献和已发表数据,效果以质量调整无进展生存年定义。

主要发现

  • 腹腔镜策略平均额外成本为7034美元。
  • 腹腔镜策略平均额外获得4.1个月质量调整无进展生存期。
  • 增量成本效果比为每额外质量调整无进展生存年20376美元。
  • 腹腔镜策略在支付意愿阈值范围内均具有成本效果。
  • 腹腔镜的获益受严重并发症及其相关成本的减轻影响。

关键数值与推荐

  • 支付意愿阈值设定为每质量调整无进展生存年50000美元。

临床怎么用

  • 对于考虑初次肿瘤细胞减灭术的晚期卵巢癌患者,可考虑行腹腔镜评估以分诊至初次肿瘤细胞减灭术或新辅助化疗联合间歇性肿瘤细胞减灭术。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine if laparoscopy is a cost-effective way to assess disease resectability in patients with newly diagnosed advanced ovarian cancer. METHODS: A cost-effectiveness analysis from a health care payer perspective was performed comparing two strategies: (1) a standard evaluation strategy, where a conventional approach to treatment planning was used to assign patients to either primary cytoreduction (PCS) or neoadjuvant chemotherapy with interval cytoreduction (NACT), and (2) a laparoscopy strategy, where patients considered candidates for PCS would undergo laparoscopy to triage between PCS or NACT based on the laparoscopy-predicted likelihood of complete gross resection. A microsimulation model was developed that included diagnostic work-up, surgical and adjuvant treatment, perioperative complications, and progression-free survival (PFS). Model parameters were derived from the literature and our published data. Effectiveness was defined in quality-adjusted PFS years. Results were tested with deterministic and probabilistic sensitivity analysis (PSA). The willingness-to-pay (WTP) threshold was set at $50,000 per year of quality-adjusted PFS. RESULTS: The laparoscopy strategy led to additional costs (average additional cost $7034) but was also more effective (average 4.1 months of additional quality-adjusted PFS). The incremental cost-effectiveness ratio (ICER) of laparoscopy was $20,376 per additional year of quality-adjusted PFS. The laparoscopy strategy remained cost-effective even as the cost added by laparoscopy increased. The benefit of laparoscopy was influenced by mitigation of serious complications and their associated costs. The laparoscopy strategy was cost-effective across a range of WTP thresholds. CONCLUSIONS: Performing laparoscopy is a cost-effective way to improve primary treatment planning for patients with untreated advanced ovarian cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Harrison RF, Cantor SB, Sun CC, et al. Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer. Gynecol Oncol. 2021. PMID: 33536126. doi:10.1016/j.ygyno.2021.01.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。